Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06435221 · ClinicalTrials.gov registry record · Phase 3
Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette Smokers
A Phase 3 study, sponsored by Achieve Life Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 479
- Enrollment target
NCT06435221 is a Phase 3 study that has completed, run by Achieve Life Sciences. The registered enrollment target is 479 participants.
The verdict
NCT06435221, a Phase 3 study, has completed, sponsored by Achieve Life Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 479 participants
- Enrollment target
Study Summary
Safety assessment of long-term 3 mg cytisinicline three times daily (TID) exposure for 52 weeks is the main purpose of this study, conducted in the United States.
Interventions
- DRUG Cytisinicline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 479 participants |
| Start Date | 2024-05-28 |
| Est. Completion | 2025-10-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06435221
The ClinicalTrials.gov registry entry for NCT06435221 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 479 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Achieve Life Sciences, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cytisinicline is the first listed.
NCT06435221 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06435221 about?
NCT06435221 is a clinical study titled "Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette Smokers". Safety assessment of long-term 3 mg cytisinicline three times daily (TID) exposure for 52 weeks is the main purpose of this study, conducted in the United States.
What is the current status of trial NCT06435221?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 479 participants. The study started on 2024-05-28. Estimated completion is 2025-10-06.
What interventions are being tested in trial NCT06435221?
The interventions under investigation include: Cytisinicline (DRUG).
Who is sponsoring clinical trial NCT06435221?
This trial is sponsored by Achieve Life Sciences, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.